TRAVERE THERAPEUTICSCS INC
TRAVERE THERAPEUTICSCS INC
Share · US89422G1076 · TVTX · A2QHYP (XNAS)
Overview Financial Indicators
15,32 USD
4,08 % 0,60 USD
NASDAQ (XNAS) · Current prices and charts at MoneyPeak
06.06.2025 20:00

Current Prices from TRAVERE THERAPEUTICSCS INC

ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
TVTX
USD
06.06.2025 20:00
15,32 USD
14,72 USD
+4,08 %

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
0,00 % 2,00 % -23,21 % -19,11 % -20,29 % 111,89 % -5,84 %

Company Profile for TRAVERE THERAPEUTICSCS INC Share

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Invested Funds

The following funds have invested in: TRAVERE THERAPEUTICSCS INC invested:

Fund
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Vol. in million
43,83
Percentage (%)
0,10 %

Company Data

Name TRAVERE THERAPEUTICSCS INC
Company Travere Therapeutics, Inc.
Symbol TVTX
Website https://www.travere.com
Primary Exchange XNAS NASDAQ
WKN A2QHYP
ISIN US89422G1076
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Dr. Eric M. Dube Ph.D.
Market Capitalization 1 Mrd.
Country United States of America
Currency USD
Employees 0,4 T
Address 3611 Valley Centre Drive, 92130 San Diego
IPO Date 2012-11-08

ID Changes

Date From To
19.11.2020 RTRX TVTX

Ticker Symbols

Name Symbol
NASDAQ TVTX

More Shares

Investors who TRAVERE THERAPEUTICSCS INC hold also have the following shares in their portfolio:
ACTIVISION BLIZZARD INC
ACTIVISION BLIZZARD INC Share
ADTRAN HOLDINGS INC
ADTRAN HOLDINGS INC Share
AMGEN INC
AMGEN INC Share
ASSEMBLY BIOSCIENCES INC
ASSEMBLY BIOSCIENCES INC Share
AUTODESK INC
AUTODESK INC Share
BROADCO INC
BROADCO INC Share
CISCO SYSTEMS INC
CISCO SYSTEMS INC Share
COSTCO WHOLESALE CORP
COSTCO WHOLESALE CORP Share
INTEL CORP
INTEL CORP Share
LANDWIRT.R.BK 18/28SK MTN
LANDWIRT.R.BK 18/28SK MTN Bond
MICROSOFT CORP
MICROSOFT CORP Share
UBS LUX STR.BAL. EO P-DIS
UBS LUX STR.BAL. EO P-DIS Fund
WALGREENS BOOTS ALLIANCE INC
WALGREENS BOOTS ALLIANCE INC Share
WRTS LKD A SHS TBEA CO LTD 12/12/2022
WRTS LKD A SHS TBEA CO LTD 12/12/2022 Verbriefte Derivate
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025